9.49
0.21%
+0.02
Dopo l'orario di chiusura:
9.32
-0.17
-1.79%
Benitec Biopharma Inc Borsa (BNTC) Ultime notizie
Benitec Biopharma (NASDAQ:BNTC) Shares Cross Above Fifty Day Moving Average of $6.50 - MarketBeat
MarketBeat
Trend Tracker for (BNTC) - Stock Traders Daily
Stock Traders Daily
Benitec Biopharma Releases Third Quarter 2024 Financial Results and Provides Operational Update - Markets Insider
Markets Insider
Benitec Biopharma Releases Third Quarter 2024 Financial Results and Provides Operational Update - Yahoo Finance
Yahoo Finance
(BNTC) Technical Pivots with Risk Controls - Stock Traders Daily
Stock Traders Daily
Benitec Biopharma to Participate in the Citizens JMP Life Science Conference - GlobeNewswire
GlobeNewswire
Benitec Biopharma to Participate in the Citizens JMP Life Science Conference - GlobeNewswire
GlobeNewswire
Benitec Biopharma's $40 Million Equity Financing Deal - TipRanks.com - TipRanks
TipRanks
Benitec Biopharma Reports Positive Interim Clinical Trial Data for First OPMD Subject Treated with BB-301 in Phase 1b/2a Study
GlobeNewswire Inc.
Benitec Biopharma Announces Oversubscribed Private Placement Financing of $40.0 Million
GlobeNewswire Inc.
Benitec Biopharma Reports Positive Interim Clinical Trial Data for First OPMD Subject Treated with BB-301 in Phase 1b ... - GlobeNewswire
GlobeNewswire
Wall Street Breakfast: The Week Ahead
Seeking Alpha
Benitec Biopharma to Host Virtual R&D Day to Discuss BB-301 Clinical Program in Oculopharyngeal Muscular ... - GlobeNewswire
GlobeNewswire
Here's Why Benitec Biopharma Inc.'s (NASDAQ:BNTC) CEO Compensation Is The Least Of Shareholders Concerns - Yahoo Finance
Yahoo Finance
Citadel Advisors LLC Acquires New Stake in Benitec Biopharma Inc - Yahoo Finance
Yahoo Finance
JANUS HENDERSON GROUP PLC Acquires New Stake in Benitec Biopharma Inc - Yahoo Finance
Yahoo Finance
Benitec Biopharma Inc. Announces Closing of $30 Million Underwritten Public Offering - Yahoo Finance
Yahoo Finance
Benitec Biopharma Inc. Announces Pricing of $30 Million Underwritten Public Offering - Yahoo Finance
Yahoo Finance
Benitec Biopharma Announces 1-for-17 Reverse Stock Split Effective July 26, 2023 - Yahoo Finance
Yahoo Finance
Benitec's BB-301 cleared to enter clinic in US for oculopharyngeal muscular dystrophy-related dysphagia - BioWorld Online
BioWorld Online
Global RNAi Therapeutics Market 2023 to 2027: Featuring Sanofi, Alnylam Pharmaceuticals, Arrowhead ... - Yahoo Finance
Yahoo Finance
7 Cheap Robinhood Stocks Under $1 To Watch Trading For Pennies - Penny Stocks
Penny Stocks
Benitec Biopharma begins OPMD subject enrolment - Clinical Trials Arena
Clinical Trials Arena
Benitec Biopharma Enrolls First OPMD Subject into the Clinical Development Program - GlobeNewswire
GlobeNewswire
Benitec Biopharma Provides Overview of the BB-301 Phase 1b/2a Clinical Trial Design for 2022 - PR Newswire
PR Newswire
Benitec Biopharma Announces Successful Results from the Interim Analysis of the BB-301 Pilot Dosing Study - PR Newswire
PR Newswire
Benitec Biopharma Announces Closing of $11.5 Million Public Offering and Full Exercise of Underwriter's Option to ... - PR Newswire
PR Newswire
Benitec's BB-301 for Treating OPMD Is Granted FDA Orphan Drug Status - Muscular Dystrophy News
Muscular Dystrophy News
BNTC Stock Price and Chart — NASDAQ:BNTC - TradingView
TradingView
Benitec Biopharma (BNTC) Stock Price, News & Analysis - MarketBeat
MarketBeat
Dr Graham’s patented elixir: Gene silencing, miracle cures and Balmain’s biggest biotech company - The Monthly
The Monthly
Acquisition of Tacere Therapeutics and Phase I/II Ready HCV Program - Technology Networks
Technology Networks
Capitalizzazione:
|
Volume (24 ore):